FAILED TRIAL: CAPItello-290 Ph 3 trial of Truqap (capivasertib) + chemo in locally advanced, inoperable or metastatic TNBC patients with PI3KCA/AKT1/PTEN alterations did not meet the dual primary endpoints of OS improvement June 25, 2024
Pivotal Ph 3 Trial of Trilaciclib to continue in metastatic TNBC Following Interim Analysis by IDMC February 26, 2024
Ph 3 PRESERVE 2 trial of Cosela in mTNBC to continue to final analysis following IDMC recommendation February 26, 2024
Two Ph 3 Trials of Datopotamab Deruxtecan + Imfinzi Initiated in Patients Across Two Breast Cancer Subtypes January 10, 2024
Tecentriq subcutaneous (SC) is approved in Great Britain for all indications of IV Tecentriq, offering a faster, more convenient option to receive treatment September 6, 2023
Enrollment opens for Keytruda® Arm in Ongoing Breast Cancer alpha-lactalbumin and AMHR2-ED-targeting Vaccine Clinical Trial August 16, 2023
New Results from Ph 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an ADC May 18, 2023
Volastra Therapeutics in-licenses Clinical Stage KIF18A Inhibitor And Secures $60 Million in Series A Funding To Further Advance Cancer-Focused Pipeline March 15, 2023
Encouraging early efficacy data from ModiFY Ph 1/2 trial announced: Modi-1 monotherapy showed PR and SD in SCCHN, ovarian, or TNBC patients February 22, 2023
Upcoming 2023 Readouts from Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib announced January 17, 2023
Calidi Biotherapeutics Receives Funding from the California Institute for Regenerative Medicine (CIRM) to Advance SuperNova-1 and NeuroNova-2 Development Programs December 19, 2022
MARIO-3 Updates reported in Patients with 1L mTNBC Suggesting Potential Long-Term Patient Benefit of Eganelisib November 23, 2022
Initial Results From Ph 2 Trial Demonstrate Potential Of Trilaciclib To Reduce Adverse Events Related To An ADC November 16, 2022
Enrollment Completed in Global Multi-Center Ph 3 Clinical Trial of Trilaciclib in Patients with mTNBC October 19, 2022
KEYTRUDA® Receives Four New Approvals in Japan, Including in High-Risk Early-Stage TNBC October 5, 2022
FDA approved Lytgobi (futibatinib) for adults with advanced intrahepatic cholangiocarcinoma (iCCA) who have FGFR2 gene fusions or other rearrangements October 5, 2022
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Adjuvant Monotherapy After Surgery for Locally Advanced or Early-Stage Triple-Negative Breast Cancer at High Risk of Recurrence June 14, 2022
Modi-1 Ph 1/2 trial open for recruitment in patients with TNBC, ovarian cancer, head and neck cancer, and RCC April 12, 2022
